177 related articles for article (PubMed ID: 25964779)
1. Targeting the IGF-1R: The Tale of the Tortoise and the Hare.
Crudden C; Girnita A; Girnita L
Front Endocrinol (Lausanne); 2015; 6():64. PubMed ID: 25964779
[TBL] [Abstract][Full Text] [Related]
2. The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?
Crudden C; Ilic M; Suleymanova N; Worrall C; Girnita A; Girnita L
Growth Horm IGF Res; 2015 Feb; 25(1):2-12. PubMed ID: 25466906
[TBL] [Abstract][Full Text] [Related]
3. Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.
Girnita L; Worrall C; Takahashi S; Seregard S; Girnita A
Cell Mol Life Sci; 2014 Jul; 71(13):2403-27. PubMed ID: 24276851
[TBL] [Abstract][Full Text] [Related]
4. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions.
Tufail M; Wu C
Ther Deliv; 2022 Mar; 13(3):167-186. PubMed ID: 35029130
[TBL] [Abstract][Full Text] [Related]
5. Role of insulin-like growth factor 1 receptor signalling in cancer.
Larsson O; Girnita A; Girnita L
Br J Cancer; 2007; 96 Suppl():R2-6. PubMed ID: 17393577
[TBL] [Abstract][Full Text] [Related]
6. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
7. Targeting IGF-1 signaling pathways in gynecologic malignancies.
Bruchim I; Werner H
Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
10. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.
Zha J; Lackner MR
Clin Cancer Res; 2010 May; 16(9):2512-7. PubMed ID: 20388853
[TBL] [Abstract][Full Text] [Related]
11. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells.
Shimizu M; Deguchi A; Hara Y; Moriwaki H; Weinstein IB
Biochem Biophys Res Commun; 2005 Sep; 334(3):947-53. PubMed ID: 16053920
[TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
13. The viral G protein-coupled receptor ORF74 unmasks phospholipase C signaling of the receptor tyrosine kinase IGF-1R.
de Munnik SM; van der Lee R; Velders DM; van Offenbeek J; Smits-de Vries L; Leurs R; Smit MJ; Vischer HF
Cell Signal; 2016 Jun; 28(6):595-605. PubMed ID: 26931381
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2.
Nair PN; De Armond DT; Adamo ML; Strodel WE; Freeman JW
Oncogene; 2001 Dec; 20(57):8203-14. PubMed ID: 11781836
[TBL] [Abstract][Full Text] [Related]
15. The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy.
Bähr C; Groner B
Growth Horm IGF Res; 2004 Aug; 14(4):287-95. PubMed ID: 15231297
[TBL] [Abstract][Full Text] [Related]
16. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
Scagliotti GV; Novello S
Cancer Treat Rev; 2012 Jun; 38(4):292-302. PubMed ID: 21907495
[TBL] [Abstract][Full Text] [Related]
17. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells.
Shimizu M; Shirakami Y; Sakai H; Tatebe H; Nakagawa T; Hara Y; Weinstein IB; Moriwaki H
Cancer Lett; 2008 Apr; 262(1):10-8. PubMed ID: 18164805
[TBL] [Abstract][Full Text] [Related]
18. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
[TBL] [Abstract][Full Text] [Related]
19. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
